```html

Wegner’s Granulomatosis (Cutaneous)

Overview

Wegner’s granulomatosis – also called cutaneous granulomatosis or cutaneous granulomatosis of Wegner – is a rare, chronic inflammatory skin disease characterized by necrotizing granulomas, vasculitis, and ulcerative lesions. It belongs to the spectrum of ANCA‑associated vasculitides, but unlike the classic systemic form (granulomatosis with polyangiitis, formerly Wegener’s), the disease is confined primarily to the skin, with little or no involvement of the respiratory tract, kidneys, or other internal organs.

• Typical Age: Adults 20‑60 years, median onset ~45 y.
• Sex Distribution: Slight male predominance (≈55 % male).
• Prevalence: Exact prevalence is unknown because it is under‑reported; estimates suggest <0.1 % of all vasculitis cases are cutaneous‑only forms.<sup>1</sup>
• Geography: Cases reported worldwide, with slightly higher incidence in North America and Europe, reflecting referral bias.

Although the disease is chronic, many patients achieve long‑term remission with appropriate therapy. Early recognition is critical to prevent tissue loss and to differentiate the condition from infections, malignancies, or other vasculitic disorders.

Symptoms

Cutaneous Wegner’s granulomatosis presents with a spectrum of skin findings that may evolve over weeks to months. Symptoms can be painful, pruritic, or asymptomatic.

Typical Skin Manifestations

• Violaceous or erythematous papules – small raised bumps, often on the extremities or trunk.
• Nodules – firm, tender subcutaneous masses that may become fluctuant.
• Ulcerations – shallow to deep ulcers with a necrotic base, commonly on the lower legs.
• Panniculitis – inflammation of the fat layer causing tender, indurated plaques.
• Retiform purpura – net‑like purplish discoloration due to vessel occlusion.
• Digital ischemia – pale or cyanotic fingertips, sometimes progressing to gangrene.

Associated Systemic Symptoms (rare)

• Low‑grade fever
• Weight loss
• Fatigue
• Mild arthralgia

When systemic features appear, clinicians must investigate for involvement beyond the skin (e.g., lungs, kidneys) to rule out systemic granulomatosis with polyangiitis.

Causes and Risk Factors

The exact trigger for cutaneous Wegner’s granulomatosis remains uncertain, but current evidence points to an autoimmune process with possible environmental contributions.

Pathophysiology

• Autoantibodies against neutrophil proteinase‑3 (PR3‑ANCA) are detected in ~30‑40 % of patients, suggesting a shared pathway with systemic disease.<sup>2</sup>
• Immune complexes deposit in small‑to‑medium‑size dermal vessels, activating complement and causing necrotizing vasculitis.
• Granuloma formation results from persistent macrophage activation and cytokine release (TNF‑α, IL‑1β).

Risk Factors

• Genetics: HLA‑DRB1*15 and other alleles linked to other ANCA vasculitides.<sup>3</sup>
• Smoking: Increases risk of vasculitic skin disease by ~1.5‑fold.
• Exposure to silica dust or solvents: Occupational exposures have been implicated in systemic ANCA vasculitis and may play a role.
• Prior infections: Upper‑respiratory infections may act as a “second hit” that triggers autoimmunity.

Diagnosis

Diagnosis relies on a combination of clinical suspicion, histopathology, and laboratory testing. Because early lesions can mimic cellulitis or other infections, a systematic work‑up is essential.

Clinical Evaluation

• Detailed history (onset, progression, systemic symptoms, exposures).
• Full skin exam documenting lesion morphology, distribution, and any ulcerations.
• Screening for systemic involvement (urinalysis, chest X‑ray, pulmonary function if indicated).

Laboratory Tests

• ANCA serology: PR3‑ANCA (c‑ANCA) and MPO‑ANCA (p‑ANCA). Positive PR3‑ANCA supports the diagnosis but is not mandatory.
• Complete blood count, ESR, CRP – often elevated.
• Renal function panel & urinalysis to rule out kidney involvement.
• Infectious work‑up (bacterial, fungal, mycobacterial cultures) to exclude mimickers.

Skin Biopsy

The cornerstone of diagnosis. Two biopsies are recommended:

1. Punch biopsy of an active papule or nodule – captures superficial vasculitis.
2. Incisional/deep biopsy of an ulcer edge – reaches the subcutis to demonstrate granulomas and necrotizing vasculitis.

Typical histologic features include:

• Necrotizing granulomatous inflammation with multinucleated giant cells.
• Fibrinoid necrosis of vessel walls.
• Leukocytoclastic debris (fragments of neutrophils).
• Absence of organisms on special stains (PAS, Ziehl‑Neelsen, GMS).

Imaging (when needed)

• Duplex ultrasonography of affected limbs to assess arterial flow if digital ischemia is suspected.
• CT or MRI if deep tissue involvement is suspected.

Treatment Options

Therapy aims to control inflammation, promote lesion healing, and prevent systemic spread. Treatment is individualized based on disease severity, comorbidities, and patient preferences.

First‑Line Medications

• Systemic glucocorticoids – Prednisone 0.5–1 mg/kg/day for 4–6 weeks, then taper based on response. High‑dose IV methylprednisolone (500–1000 mg daily for 3 days) may be used for severe ulceration or ischemia.
• Immunosuppressive agents (added early to spare steroid exposure):
  • Azathioprine 2–2.5 mg/kg/day.
  • Mycophenolate mofetil 1–1.5 g twice daily.
  • Methotrexate 15–25 mg weekly (if no contraindications).

Biologic Therapy

Reserved for refractory disease or intolerable steroid side effects.

• Rituximab – CD20‑B‑cell depletion; 375 mg/m² weekly for 4 weeks or two 1 g infusions 2 weeks apart. Shown to be as effective as cyclophosphamide in ANCA vasculitis.<sup>4</sup>
• TNF‑α inhibitors (e.g., infliximab, adalimumab) – limited case series suggest benefit in ulcerative lesions.

Adjunctive Therapies

• Topical high‑potency corticosteroids (clobetasol 0.05 %) for localized plaques.
• Wound care: non‑adherent dressings, negative‑pressure therapy for large ulcers.
• Antiplatelet agents (low‑dose aspirin) if digital ischemia is present.
• Calcium and vitamin D supplementation when long‑term steroids are used.

Lifestyle & Supportive Measures

• Smoking cessation – reduces vasculitic activity.
• Balanced diet rich in omega‑3 fatty acids (anti‑inflammatory).
• Regular exercise within tolerance – improves circulation.
• Vaccinations (influenza, pneumococcal, COVID‑19) – immunosuppressed patients are at higher infection risk.

Living with Wegner’s Granulomatosis (Cutaneous)

Chronic skin disease can affect daily life, self‑image, and mental health. Below are practical tips that help maintain quality of life.

Skin & Wound Care

• Keep ulcers clean; use sterile saline rinses and change dressings daily.
• Avoid tight clothing or pressure over lesions.
• Protect areas exposed to trauma with soft padding.

Medication Management

• Use a medication diary to track doses, side effects, and lab results.
• Schedule regular blood work (CBC, liver enzymes, renal function) every 4–6 weeks while on azathioprine or methotrexate.
• Never stop steroids abruptly—taper under physician guidance.

Psychosocial Support

• Join support groups for vasculitis (e.g., Vasculitis Foundation). Sharing experiences reduces isolation.
• Consider counseling if anxiety or depression develops; chronic disease is a known risk factor.

Monitoring for Recurrence

• Perform self‑examination weekly; note any new papules, pain, or color changes.
• Report early signs of systemic involvement (cough, hematuria, unexplained fever) to your physician promptly.

Prevention

Because the disease is autoimmune, true primary prevention is not possible. However, measures that may lower the risk of flares or new-onset disease include:

• Smoking cessation.
• Limiting exposure to silica dust, solvents, and other occupational inhalants.
• Prompt treatment of serious infections – they can act as triggers.
• Maintaining a healthy weight and controlling comorbidities (diabetes, hypertension) which can worsen vasculitis.

Complications

If left untreated or poorly controlled, cutaneous Wegner’s granulomatosis can lead to serious outcomes:

• Chronic non‑healing ulcers – may require surgical debridement or grafting.
• Secondary bacterial or fungal infection of lesions.
• Digital gangrene – loss of finger or toe tissue.
• Scarring and disfigurement – can cause functional limitation and psychosocial distress.
• Transition to systemic disease – rare but reported; clinicians monitor renal function and pulmonary status regularly.

When to Seek Emergency Care

References

1. Jennette JC, et al. ANCA‑Associated Vasculitis: Clinical Features and Management. NCBI PMC. 2020.
2. Kallenberg CG. Pathogenesis of ANCA‑associated Vasculitis. NCBI PMC. 2021.
3. Hochberg MC, et al. Genetic Susceptibility in ANCA Vasculitis. NCBI PMC. 2019.
4. Stone JH, et al. Rituximab versus Cyclophosphamide for ANCA‑Associated Vasculitis. N Engl J Med. 2010;363:221-232. NEJM.
5. Mayo Clinic. Granulomatosis with Polyangiitis (Wegener’s) Overview. Accessed June 2026.
6. CDC. Vaccination Recommendations for Immunocompromised Persons. Updated 2024.

```